News coverage about Infinity Pharmaceuticals (NASDAQ:INFI) has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies negative and positive news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Infinity Pharmaceuticals earned a news sentiment score of 0.15 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 46.2006514326586 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the news headlines that may have effected Accern Sentiment’s analysis:
- Infinity Pharmaceuticals: Cheap With A Key Data Readout Coming (seekingalpha.com)
- Rounds Report: Solid Biosciences Made Big Waves While The FDA Approved Eversense (seekingalpha.com)
- Bvf Partners L. P/Il Buys 425,531 Shares of Infinity Pharmaceuticals Inc. (INFI) Stock (americanbankingnews.com)
- Infinity Pharmaceuticals Inc. (INFI) Major Shareholder Bvf Partners L. P/Il Acquires 3,516,560 Shares (americanbankingnews.com)
- Sell or Hold action? Infinity Pharmaceuticals, Inc. (INFI) (nasdaqplace.com)
Infinity Pharmaceuticals traded up $0.33, reaching $2.05, during trading on Friday, Marketbeat reports. The company had a trading volume of 2,939,804 shares, compared to its average volume of 751,159. Infinity Pharmaceuticals has a 1-year low of $0.93 and a 1-year high of $3.75. The stock has a market capitalization of $96.44 million, a P/E ratio of -2.47 and a beta of 2.58.
A number of research firms recently issued reports on INFI. ValuEngine raised shares of Infinity Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, June 2nd. Zacks Investment Research cut shares of Infinity Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, May 16th. Finally, Seaport Global Securities began coverage on shares of Infinity Pharmaceuticals in a research note on Thursday, May 31st. They issued a “buy” rating and a $4.00 price target on the stock.
In other news, major shareholder Bvf Partners L. P/Il acquired 425,531 shares of the firm’s stock in a transaction on Thursday, June 21st. The shares were bought at an average price of $1.65 per share, for a total transaction of $702,126.15. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, major shareholder Value Fund L. P. Biotechnology acquired 1,510,000 shares of the firm’s stock in a transaction on Tuesday, April 10th. The stock was purchased at an average price of $1.97 per share, for a total transaction of $2,974,700.00. The disclosure for this purchase can be found here. Insiders purchased a total of 5,452,091 shares of company stock worth $9,479,150 in the last three months. 11.45% of the stock is owned by corporate insiders.
Infinity Pharmaceuticals Company Profile
Infinity Pharmaceuticals, Inc, a biopharmaceutical company, develops medicines for people with cancer in the United States. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study.
Receive News & Ratings for Infinity Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.